Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes
- PMID: 32197856
- DOI: 10.1016/j.cllc.2020.02.013
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes
Abstract
Introduction: Small-cell lung cancer (SCLC) is highly responsive to chemotherapy (CT) and one of the few malignancies treated in hospitalized patients with poor Eastern Cooperative Oncology Group (ECOG) performance status (PS). Because of the little current information available on the outcomes experienced by hospitalized patients with SCLC receiving CT, we explored the outcomes for these patients to improve the evidence base for practice.
Materials and methods: We conducted a retrospective cohort study to evaluate patients with a diagnosis of SCLC and treated with CT during a 10-year period. Progression-free survival (PFS) and overall survival (OS) were evaluated according to site of first CT (inpatient vs. outpatient) and PS. Multivariable analysis was completed to assess for independent survival predictors.
Results: A total of 530 patients with SCLC were treated, with 82 (15%) receiving their first CT in hospital. Inpatients had a greater burden of disease and poorer PS. Neutropenia, thrombocytopenia, nephrotoxicity, and fatigue were all experienced less often by the inpatient cohort (P < .001, P < .001, P < .001, and P = .007, respectively). For inpatients and outpatients, the OS rate at 12, 24, and 60 months was 22%, 9%, and 7% and 43%, 20%, and 9%, respectively (P < .001 for all). The median PFS and OS were longer for outpatients and highly functional patients. On multivariable analysis, ECOG PS was an independent predictor of the outcome and the site of first CT was not (P = .04 and P = .49, respectively).
Conclusion: Patients with SCLC initially treated as inpatients and those with poor functional status had shorter PFS and OS; however, some experienced long-term survival, including 5-year survival of 7% for the inpatient cohort and 5% for the ECOG PS 3-4 cohort. CT toxicities were less common in the inpatient cohort, validating that administration of CT in hospital should be considered for these patients because they could experience a meaningful long-term response to therapy.
Keywords: ECOG; Inpatient; Population-based; Prognosis; Retrospective cohort.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.Lung Cancer. 2012 Dec;78(3):276-81. doi: 10.1016/j.lungcan.2012.09.002. Epub 2012 Oct 6. Lung Cancer. 2012. PMID: 23043970
-
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.Lung Cancer. 2014 Sep;85(3):420-8. doi: 10.1016/j.lungcan.2014.05.003. Epub 2014 May 13. Lung Cancer. 2014. PMID: 24997137 Clinical Trial.
-
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006. Epub 2015 Apr 24. Clin Lung Cancer. 2015. PMID: 25983005
-
Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.Curr Probl Cancer. 2020 Jun;44(3):100550. doi: 10.1016/j.currproblcancer.2020.100550. Epub 2020 Jan 20. Curr Probl Cancer. 2020. PMID: 31987521
-
A systematic review of survival following anti-cancer treatment for small cell lung cancer.Lung Cancer. 2020 Mar;141:44-55. doi: 10.1016/j.lungcan.2019.12.015. Epub 2020 Jan 11. Lung Cancer. 2020. PMID: 31955000
Cited by
-
The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.Front Immunol. 2024 Feb 29;15:1333850. doi: 10.3389/fimmu.2024.1333850. eCollection 2024. Front Immunol. 2024. PMID: 38487532 Free PMC article.
-
Spatial transcriptomics reveals macrophage domestication by epithelial cells promotes immunotherapy resistance in small cell lung cancer.NPJ Precis Oncol. 2025 Jul 24;9(1):252. doi: 10.1038/s41698-025-01005-5. NPJ Precis Oncol. 2025. PMID: 40702109 Free PMC article.
-
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.Curr Oncol. 2022 Dec 8;29(12):9744-9752. doi: 10.3390/curroncol29120765. Curr Oncol. 2022. PMID: 36547179 Free PMC article.
-
Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.Front Oncol. 2022 Sep 15;12:1002385. doi: 10.3389/fonc.2022.1002385. eCollection 2022. Front Oncol. 2022. PMID: 36185266 Free PMC article.
-
Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.Front Immunol. 2022 Nov 30;13:1059331. doi: 10.3389/fimmu.2022.1059331. eCollection 2022. Front Immunol. 2022. PMID: 36532013 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical